Glover Nicholas 4
4 · Sierra Oncology, Inc. · Filed Mar 7, 2018
Insider Transaction Report
Form 4
Glover Nicholas
DirectorCEO and President
Transactions
- Award
Stock Option (right to buy)
2018-03-06+562,780→ 562,780 totalExercise: $2.36Exp: 2028-03-06→ Common Stock (562,780 underlying)
Footnotes (1)
- [F1]The option vests as to 25% of the total shares on January 1, 2019, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on January 1, 2022, subject to the reporting person's provision of service to the issuer on each vesting date.